Zhong Jin Zai Xian·2025-05-16 02:42Core Insights - The launch of the domestic antiviral drug Yisuda® (generic name: Moshurashave tablets) marks a significant advancement in China's flu treatment options, being the first drug targeting the flu virus RNA polymerase PA subunit developed in the country [1][3] - Yisuda® is designed for the treatment of both type A and B influenza in adolescents and adults aged 12 and above, requiring only a single dose for the entire treatment course, which is a notable improvement over traditional flu medications [1][3] - The drug has a low resistance mutation rate of less than 1%, indicating more stable treatment effects compared to similar antiviral drugs [3] Industry Context - The flu poses a serious public health threat, significantly impacting daily life and work, with China's antiviral market historically reliant on imported medications, leading to shortages during peak flu seasons [3] - The introduction of Yisuda® fills a gap in the domestic innovative drug market, providing a new treatment option for Chinese patients and ensuring stable drug supply through local production [3] - JD Health has established itself as a leading platform for the online launch of new specialty drugs, leveraging its supply chain capabilities to enhance accessibility and provide timely treatment options for patients [4]